NCT05712720
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants With Diabetic Macular Edema (DME)
Rezolute·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Diabetic Macular Edema
- Drug/Device/Intervention
- Experimental: Group 1
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Rezolute
- Location
- Phoenix,Beverly Hills,Fullerton,Modesto,Santa Barbara,Coral Springs,Winter Haven,Augusta,Oak Forest,Hagerstown,Royal Oak,Saint Louis Park,Saint Louis,Reno,Bloomfield,Great Neck,New York,Springfield,La, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 06, 2023
- End date
- Jan 01, 2024
- Enrollment
- 100 participants
Primary outcome
Safety Events,Change in Central Subfield Thickness
Summary
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in
 patients with Diabetic Macular Edema.
ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05712720
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05712720 through Pure Global AI's free database. This Phase 2 trial is sponsored by Rezolute and is currently Recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.